AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Johnson & Johnson convinced a U.S. appeals court on Tuesday to reject a bid from generic drugmakers Teva and Viatris to ...

Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The sto ...

Medically reviewed by Michael MacIntyre, MDSchizophrenia medication falls under two main categories: older, first-generation, or "typical" antipsychotics and newer drugs for schizophrenia known as ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect.

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary promise in the bout against obesity, helping patients lose an average of ...